journal article·2023-04-28

Multifaceted Pt Nanoclusters for Targeting Recognition, Cellular Uptake, and Therapy In Vivo and In Vitro in Chronic Myeloid Leukemia Cells

Xin Huang, Zengbei Li, Zhongqing Xiao, Xinjie Deng, Chaoyang Deng, Xing Chen, Shaobo Wang, Haijuan Du, Mengjun Zhang, Haodi Yue, Jie Wu, Hongyun Li

ACS Applied Nano Materials· Volume 6· Issue 8
Publisher page

Abstract

In the past few years, platinum nanomaterials (Pt NMs) have gained attraction owing to their ability to address the drawbacks of classical Pt-based chemotherapy drugs including drug resistance and clinical side effects, which have been preliminarily used in lung cancer, liver cancer, gynecological cancer, etc. In order to investigate the effect of Pt NMs on hematopoietic tumors, ultra-small Pt nanoclusters (Pt NCs) were employed to clarify their targeting recognition, cellular uptake, and effective therapy in vivo for chronic myeloid leukemia (CML) cells. Through the facile surface modification of Pt NCs with anti-CD19 to form the anti-CD19-Pt NC composite, the specific aggregation in BV173 cells could be realized based on their high protein expression of CD19 in comparison to that in CD19-negative K562 cells. Furthermore, the endocytic pathways of Pt NCs in K562 and BV173 cells were investigated by qualitative and quantitative analyses via inductively coupled plasma-optical emission spectroscopy and flow cytometry. It was observed that Pt NCs entered into the K562 cells mainly through the caveolin-dependent endocytic pathway and in BV173 cells primarily via phagocytosis and micropinocytosis. Moreover, these Pt NCs exerted an excellent inhibitory effect on proliferation, migration, and invasion of hematopoietic tumor cells and tended to gather the acidic organelles (lysosomes or endosomes), resulting in the proliferation inhibition of tumor cells by the generation of corrosive Pt. Notably, Pt NCs were significantly aggregated at the site of tumor inoculation in mice and exhibited satisfactory in vivo inhibition of the increase in tumor weight and its size under the premise of not damaging the liver and spleen. Thus, the merits of versatile Pt NCs included facile target recognition, explicit cellular uptake behavior, and therapeutic efficacy in vivo, thereby hinting at their promising prospects for the clinical diagnosis and treatment of hematological malignancies.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanocluster Synthesis and Applications · Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Light Chemical Engineering, College of Textiles, Zhongyuan University of Technology, No. 41 Zhongyuan Road (M), Zhongyuan District, Zhengzhou 450007, China

Department of Respiratory and Critical Care Medicine, The Fifth Affiliation Hospital of Zhengzhou University, No. 3 Kangfuqian Street, Erqi District, Zhengzhou 450052, China

Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095, Jiefang Road, Wuhan 430030, China

Departmengt of Gynecology, The Third Affiliated Hospital of Zhengzhou University, 7 Rehabilitation Front Street, Zhengzhou 450052, China

Department of Center for Clinical Single Cell Biomedicine, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, No. 7 Weiwu Street, Zhengzhou 450003, China

Funding

Henan Province Science and Technology Innovation Talent Program · Zhongyuan University of Technology · Science and Technology Department of Henan Province · Henan Province Foundation for University Key Teacher · National Natural Science Foundation of China · Henan Province Medical Science and Technology

References (36)

Show source-provided references
1. 10.1182/blood-2016-03-64354410.1182/blood-2016-03-643544 ↗
2. 10.31083/j.fbl270204010.31083/j.fbl2702040 ↗
3. 10.1111/j.1745-7254.2007.00680.x10.1111/j.1745-7254.2007.00680.x ↗
4. Ghosn Y. · Technol. Cancer Res. Treat. · 2019 · 18 · 110.1177/1533033819853241 ↗
5. 10.3322/caac.2165410.3322/caac.21654 ↗
6. 10.1016/j.ccm.2017.07.00110.1016/j.ccm.2017.07.001 ↗
7. 10.3389/fonc.2019.0066510.3389/fonc.2019.00665 ↗
8. 10.3324/haematol.2016.15025010.3324/haematol.2016.150250 ↗
9. 10.1038/sj.onc.120140010.1038/sj.onc.1201400 ↗
10. 10.1007/s12032-021-01462-510.1007/s12032-021-01462-5 ↗
11. 10.1016/j.anndiagpath.2006.12.00210.1016/j.anndiagpath.2006.12.002 ↗
12. 10.1039/d2cs00518b10.1039/d2cs00518b ↗
13. 10.1007/s00280-016-2976-z10.1007/s00280-016-2976-z ↗
14. 10.1016/j.scib.2017.03.00810.1016/j.scib.2017.03.008 ↗
15. 10.1016/j.jmrt.2020.06.01310.1016/j.jmrt.2020.06.013 ↗
16. 10.1016/j.nantod.2018.06.00610.1016/j.nantod.2018.06.006 ↗
17. 10.3389/fphar.2022.79780410.3389/fphar.2022.797804 ↗
18. 10.3390/ijms2102044010.3390/ijms21020440 ↗
19. 10.1016/j.ultsonch.2015.12.01310.1016/j.ultsonch.2015.12.013 ↗
20. 10.1155/2019/624872510.1155/2019/6248725 ↗
21. 10.1002/adma.20130236310.1002/adma.201302363 ↗
22. 10.1021/acscentsci.6b0019710.1021/acscentsci.6b00197 ↗
23. 10.1016/j.bbrc.2018.07.06410.1016/j.bbrc.2018.07.064 ↗
24. 10.1186/s13045-020-00962-710.1186/s13045-020-00962-7 ↗
25. 10.1093/jjco/hyq18910.1093/jjco/hyq189 ↗
26. 10.1016/j.bios.2018.03.03410.1016/j.bios.2018.03.034 ↗
27. 10.1021/acsami.7b0514510.1021/acsami.7b05145 ↗
28. 10.1177/204062071558891610.1177/2040620715588916 ↗
29. 10.1016/j.colsurfb.2019.11047810.1016/j.colsurfb.2019.110478 ↗
30. 10.1158/0008-5472.can-12-456110.1158/0008-5472.can-12-4561 ↗
31. 10.1166/jbn.2014.162510.1166/jbn.2014.1625 ↗
32. 10.1038/nrc.2016.10810.1038/nrc.2016.108 ↗
33. 10.2147/ijn.s27428910.2147/ijn.s274289 ↗
34. 10.1016/j.addr.2019.08.00410.1016/j.addr.2019.08.004 ↗
35. 10.1021/acsami.2c1514310.1021/acsami.2c15143 ↗
36. 10.1016/j.addr.2019.04.00810.1016/j.addr.2019.04.008 ↗